Company Performance - Adma Biologics (ADMA) closed at $17.70, down 1.28% from the previous trading session, underperforming the S&P 500's daily loss of 0.19% [1] - Over the past month, ADMA shares have decreased by 9.12%, lagging behind the Medical sector's gain of 0.48% and the S&P 500's gain of 2.26% [1] Upcoming Earnings - Investors are anticipating Adma Biologics' upcoming earnings disclosure, with Zacks Consensus Estimates predicting earnings of $0.57 per share and revenue of $0 million, reflecting year-over-year changes of +16.33% for earnings and 0% for revenue [2] Analyst Forecasts - Recent revisions to analyst forecasts for Adma Biologics should be monitored, as positive estimate revisions indicate optimism about the business outlook [3] Valuation Metrics - Adma Biologics is currently trading at a Forward P/E ratio of 21.87, which is a premium compared to its industry's Forward P/E of 20.92 [6] - The Medical - Biomedical and Genetics industry, to which Adma belongs, has a Zacks Industry Rank of 99, placing it in the top 41% of over 250 industries [6] Zacks Rank - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), currently rates Adma Biologics at 3 (Hold), with the consensus EPS estimate remaining steady over the past month [5]

Day One Biopharmaceuticals, Inc. (DAWN) shares rallied 26.7% in the last trading session to close at $11.33. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 6.9% gain over the past four weeks.The stock rallied after the company reported robust preliminary sales numbers for the fourth quarter and full-year 2025 related to its lead marketed drug, Ojemda. The drug is approved for treating patients aged six month ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Ardelyx (ARDX) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Ardelyx is one of 932 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Allogene Therapeutics (ALLO) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.Allogene Therapeutics is a member of our Medical group, which includes 932 different companies and currently sits at #7 in the Zacks Sector Rank. The Za ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. AIM ImmunoTech Inc. (AIM) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.AIM ImmunoTech Inc. is one of 932 individual stocks in the Medical sector. Collectively, these com ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Regeneron (REGN) . This company, which is in the Zacks Medical - Biomedical and Genetics industry, shows potential for another earnings beat.This biopharmaceutical company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters wa ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Humacyte, Inc. (HUMA) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Humacyte, Inc. is a member of our Medical group, which includes 933 different companies and currently sits at #8 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 differe ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Bristol Myers Squibb (BMY) . This company, which is in the Zacks Medical - Biomedical and Genetics industry, shows potential for another earnings beat.This biopharmaceutical company has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surpri ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Acurx Pharmaceuticals, Inc. (ACXP) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Acurx Pharmaceuticals, Inc. is a member of our Medical group, which includes 934 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Secto ...

Company Performance - Ginkgo Bioworks Holdings, Inc. (DNA) experienced a stock increase of +1.96% to $8.31, outperforming the S&P 500's daily loss of 0.74% [1] - Over the past month, the company's shares have declined by 5.12%, which is worse than the Medical sector's loss of 0.8% and the S&P 500's gain of 0.79% [1] Upcoming Earnings - The upcoming earnings release is anticipated to show an EPS of -$1.8, reflecting a 1.1% increase from the same quarter last year [2] - Revenue is forecasted at $37 million, indicating a 15.62% decrease compared to the same quarter last year [2] Fiscal Year Estimates - For the entire fiscal year, earnings are projected at -$5.94 per share, representing a 42.66% increase from the previous year [3] - Revenue for the fiscal year is estimated at $173 million, showing a 23.8% decline from the prior year [3] Analyst Estimates - Recent changes in analyst estimates for Ginkgo Bioworks are crucial as they reflect the evolving business trends [4] - Positive revisions in estimates are seen as indicators of analysts' confidence in the company's performance and profit potential [4] Zacks Rank and Industry Performance - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), currently places Ginkgo Bioworks at 3 (Hold) [6] - The Medical - Biomedical and Genetics industry, which includes Ginkgo Bioworks, holds a Zacks Industry Rank of 92, placing it in the top 38% of over 250 industries [7]